
BioCardia Inc. (BCDA) Stock Forecast & Price Target
BioCardia Inc. (BCDA) Analyst Ratings
Bulls say
BioCardia Inc is advancing its CardiAMP autologous mononuclear cell therapy platform with promising results from the Phase 3 clinical trial, which demonstrated significant reductions in heart death equivalents and major adverse cardiovascular and cerebrovascular events (MACCE), particularly among high-risk patients. The therapy showed that patients receiving the treatment in conjunction with heart failure medication experienced improved quality of life and lower mortality rates over a 24-month period. Additionally, the ongoing enrollment in its CardiALLO platform for ischemic heart failure and acute respiratory distress syndrome suggests a strong pipeline for addressing unmet medical needs in the cardiovascular and pulmonary domains, potentially driving growth for the company.
Bears say
BioCardia Inc. faces a negative outlook primarily due to its CardiAMP HF clinical program's failure to meet key composite endpoints related to heart failure, which raises concerns over the efficacy of its therapies. Furthermore, potential risks include the prospect of inconclusive clinical trials and challenges in securing sufficient funding to advance its drug candidates, which could hinder development. Additionally, the absence of projections for the CardiALLO program introduces further uncertainty regarding the company's ability to achieve its financial goals and maintain investor confidence.
This aggregate rating is based on analysts' research of BioCardia Inc. and is not a guaranteed prediction by Public.com or investment advice.
BioCardia Inc. (BCDA) Analyst Forecast & Price Prediction
Start investing in BioCardia Inc. (BCDA)
Order type
Buy in
Order amount
Est. shares
0 shares